Free Trial

NEXGEL Q4 2022 Earnings Report

NEXGEL logo
$3.37 -0.13 (-3.71%)
As of 01/21/2025 04:00 PM Eastern

NEXGEL EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

NEXGEL Revenue Results

Actual Revenue
$0.52 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NEXGEL Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

NEXGEL Earnings Headlines

Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
NEXGEL Appoints Joseph McGuire To Succeed Adam Drapczuk III As CFO
NexGel appoints McGuire as Chief Financial Officer
See More NEXGEL Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NEXGEL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NEXGEL and other key companies, straight to your email.

About NEXGEL

NEXGEL (NASDAQ:NXGL) manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

View NEXGEL Profile

More Earnings Resources from MarketBeat